Intra-Aortic Balloon Pump Management

Indications and Benefits

The American Heart Association recommends IABP for cardiogenic shock not quickly reversed with pharmacological therapy, especially in the setting of suspected coronary hypoperfusion, and serves as a stabilizing measure for angiography and prompt revascularization 1
IABP is most effective when used in conjunction with early revascularization (PCI or CABG) and provides a modest increase in cardiac output and reduces afterload, particularly beneficial in cardiogenic shock with suspected coronary hypoperfusion 1, 2
IABP decreases heart work and myocardial oxygen consumption, and may be reasonable for management of patients with refractory pulmonary congestion, with the American Heart Association and American College of Cardiology supporting its use 3, 1

Insert IABP as soon as evidence points to cardiac dysfunction, with standard insertion via the femoral artery using Seldinger technique, and consider intra-arterial monitoring for management of STEMI patients with cardiogenic shock 2
Newer generations of IABPs are driven by aorta flow detection, overcoming limitations in patients with arrhythmias, and pulmonary artery catheter monitoring may be considered for hemodynamic assessment 2, 1

For more severe cases of heart failure, ventricular assist devices (VADs) should be considered early, with options including transvalvular axial flow pumps, TandemHeart percutaneous LV assist device, and VA-ECMO for systemic circulatory support, as recommended by the American College of Cardiology and supported by high-quality evidence 2, 4, 5
VADs offer several advantages for improving renal perfusion, including being capable of taking over the full cardiac output of the failing heart, with high-quality evidence supporting this claim 2
The International Society for Heart and Lung Transplantation suggests that VADs can achieve adequate perfusion of peripheral organs, including kidneys, with moderate evidence supporting this claim 2

The IABP-SHOCK II trial showed no reduction in 30-day all-cause mortality with routine IABP use in acute coronary syndrome-related cardiogenic shock, leading the European Society of Cardiology to recommend against routine use of IABP in cardiogenic shock, with high-quality evidence supporting this recommendation 4, 5
The American Heart Association and American College of Cardiology recommend that VADs can significantly improve hemodynamics compared to IABP alone, with high-quality evidence supporting this claim 5, 2
The American College of Cardiology recommends that VADs can prevent end-organ failure by maintaining adequate systemic perfusion, with high-quality evidence supporting this claim 2

IABP is contraindicated in patients with severe aortic insufficiency, aortic regurgitation, aortic dissection, and aortic aneurysm, with absolute contraindications stated by the American College of Cardiology and the American Heart Association 2
Relative contraindications for IABP use include severe aortic stenosis and advanced peripheral and aortic vascular disease, with low-quality evidence supporting this claim 2
The European Society of Cardiology recommends that VAD candidates should not have severe renal, pulmonary, or hepatic dysfunction or active infection, with high-quality evidence supporting this claim 6

Evaluate severity of heart failure and renal dysfunction, and assess hemodynamic parameters (cardiac output, blood pressure), with low-quality evidence supporting this claim
Check for signs of end-organ hypoperfusion, optimize medical therapy, and consider IABP if coronary hypoperfusion is suspected, with moderate evidence supporting this claim 2
Consider immediate mechanical circulatory support, with high-quality evidence supporting this claim, and address RV dysfunction to prevent venous congestion, with moderate evidence supporting this claim 7
Aim to maintain adequate trans-kidney perfusion pressure (MAP-CVP >60 mmHg), with moderate evidence supporting this claim 7
Early improvement in estimated glomerular filtration rate (eGFR) occurs in approximately 85% of patients, with moderate evidence supporting this claim, and younger patients presenting in cardiogenic shock show better sustained kidney function recovery, with low-quality evidence supporting this claim 7